Evidence map›Paper›PMID 29925686›Full record

ArticleJCI insight2018

Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome.

D André d'Avignon, Patrycja Puchalska, Baris Ercal, YingJu Chang, Shannon E Martin, Mark J Graham, Gary J Patti, Xianlin Han, Peter A Crawford

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Targeting ketone body metabolism to treat fatty liver disease.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

D André d'AvignonDivision of Molecular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Patrycja PuchalskaDivision of Molecular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Baris ErcalCenter for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
YingJu ChangDivision of Molecular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Shannon E MartinCenter for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Mark J GrahamIonis Pharmaceuticals, Carlsbad, California, USA.
Gary J PattiDepartment of Chemistry, Washington University, St. Louis, Missouri, USA.
Xianlin HanCenter for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Peter A CrawfordDivision of Molecular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Sanford Burnham Prebys Medical Discovery Institute · USDiscovery Institute · USWashington University in St. Louis · USIonis Pharmaceuticals (United States) · US

Funding

KETONE BODY METABOLISM AND INTEGRATED METABOLIC HOMEOSTASISR01DK091538 · NIDDK · WASHINGTON UNIVERSITY · PI CRAWFORD, PETER A · 2011 to 2024
$6.2M
NIDDK NIH HHS R01 DK091538
6 · The paper itself

Abstract

While several molecular targets are under consideration, mechanistic underpinnings of the transition from uncomplicated nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) remain unresolved. Here we apply multiscale chemical profiling technologies to mouse models of deranged hepatic ketogenesis to uncover potential NAFLD driver signatures. Use of stable-isotope tracers, quantitatively tracked by nuclear magnetic resonance (NMR) spectroscopy, supported previous observations that livers of wild-type mice maintained long term on a high-fat diet (HFD) exhibit a marked increase in hepatic energy charge. Fed-state ketogenesis rates increased nearly 3-fold in livers of HFD-fed mice, a greater proportionate increase than that observed for tricarboxylic acid (TCA) cycle flux, but both of these contributors to overall hepatic energy homeostasis fueled markedly increased hepatic glucose production (HGP). Thus, to selectively determine the role of the ketogenic conduit on HGP and oxidative hepatic fluxes, we studied a ketogenesis-insufficient mouse model generated by knockdown of the mitochondrial isoform of 3-hydroxymethylglutaryl-CoA synthase (HMGCS2). In response to ketogenic insufficiency, TCA cycle flux in the fed state doubled and HGP increased more than 60%, sourced by a 3-fold increase in glycogenolysis. Finally, high-resolution untargeted metabolomics and shotgun lipidomics performed using ketogenesis-insufficient livers in the fed state revealed accumulation of bis(monoacylglycero)phosphates, which also accumulated in livers of other models commonly used to study NAFLD. In summary, natural and interventional variations in ketogenesis in the fed state strongly influence hepatic energy homeostasis, glucose metabolism, and the lipidome. Importantly, HGP remains tightly linked to overall hepatic energy charge, which includes both terminal fat oxidation through the TCA cycle and partial oxidation via ketogenesis.

Indexed as

AnimalsCitric Acid CycleDiet, High-FatDisease Models, AnimalGlucoseGlycogenolysisGlycogen PhosphorylaseHydroxymethylglutaryl-CoA SynthaseHyperglycemiaLipid MetabolismLiverLiver GlycogenMaleMiceMice, Inbred C57BLMitochondriaGlucoseGlycogen PhosphorylaseHydroxymethylglutaryl-CoA SynthaseLiver GlycogenPhosphatidylglycerolsFatty acid oxidationGlucose metabolismHepatologyMetabolismMouse models

Identifiers

PMID29925686
PMCPMC6124396
OpenAlexW2809304297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.